Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6237654 | 0.95 | KDM4E (0.42) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6212141 | 0.91 | KDM4E (0.43) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6243731 | 0.89 | IGF1R (0.44) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6236421 | 0.89 | HTR6 (0.40) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6237567 | 0.88 | KDM4E (0.41) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6242661 | 0.88 | STK17A (0.45) | IGF1RKDM4EALDH1A1MAPTHSD17B10 | |
| SCHEMBL6238407 | 0.87 | TBK1 (0.43) | TBK1HTR6STK17AMARK3MARK4 | |
| SCHEMBL6242731 | 0.87 | MARK3 (0.40) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6234855 | 0.87 | IGF1R (0.44) | TBK1IGF1RKDM4EALDH1A1MAPT | |
| SCHEMBL6214366 | 0.87 | PTK2 (0.43) | TBK1IGF1RKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | claimed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1578732-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | PFIZER INC | 2004-11-04 | — | — | US | disclosed |
| WO-2004056786-A2 | PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220177-A1 | Compound for the treatment of abnormal cell growth | CCNA1, CCNB1, CCNT1 | TBK1 4758/4885IGF1R 93/4885KDM4E 2081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.